Acrivon Therapeutics, INC Form 4 insider transactions

Acrivon Therapeutics' Chief Medical Officer, Mansoor Raza Mirza, was granted 174,068 stock options with a vesting schedule tied to continued service.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, received a grant of 129,760 stock options with a $1.51 exercise price, vesting over four years.

Acrivon Therapeutics' Chief Development Officer, Erick Gamelin, was granted 94,946 stock options with an exercise price of $1.51.

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, was granted options to purchase 186,728 shares of common stock at an exercise price of $1.51 per share.

Acrivon Therapeutics' CEO and EVP received significant stock option grants with a future vesting schedule, aligning executive incentives with long-term company performance.

Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, and EVP, Kristina Masson, reported tax-related dispositions of common stock following restricted stock unit vesting.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported a disposition of 659 common shares to cover tax withholdings on restricted stock unit vesting.

Acrivon Therapeutics' Chief Financial Officer, Adam D. Levy, purchased 8,832 shares of common stock at a weighted average price of $1.6983.

Acrivon Therapeutics' CEO and EVP of Business Operations, Peter Blume-Jensen and Kristina Masson, reported open market purchases of common stock.

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, purchased 10,000 shares of common stock on January 13, 2026, at a weighted average price of $1.7218 per share.

Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, reported a planned future disposition of 19,904 common shares on November 21, 2025, to cover tax obligations from restricted stock unit vesting under a Rule 10b5-1 plan.

Acrivon Therapeutics’ CAO Katharine Peterson had 99 shares withheld at $2.24 on RSU vesting, retaining 4,122 shares directly.

Chief Legal Officer Mary Miller withheld 184 ACRV shares at $2.24 to cover taxes on RSU vesting, leaving 34,555 shares owned directly.

Chief Development Officer Erick Gamelin withheld 403 ACRV shares at $2.24 to cover taxes upon RSU vesting, leaving 15,283 shares owned directly.

COO Eric Devroe had 613 ACRV shares withheld at $2.24 to cover taxes on RSU vesting, leaving 65,308 shares beneficially owned.

Acrivon insiders reported shares withheld to cover taxes upon RSU vesting, with the CEO remaining a significant holder.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported a disposition of 558 common shares for tax withholding purposes.

Acrivon Therapeutics' Chief Medical Officer, Mansoor Raza Mirza, was granted 225,000 stock options with an exercise price of $1.81, vesting over four years.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, disposed of 284 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Acrivon Therapeutics' CEO and EVP reported the withholding of shares for tax obligations related to restricted stock unit vesting.

Acrivon Therapeutics' Chief Accounting Officer, Katharine Peterson, reported the withholding of 99 common shares for tax obligations related to restricted stock unit vesting.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported a routine disposition of shares for tax withholding purposes.

Acrivon Therapeutics' Chief Development Officer, Erick Gamelin, had 403 shares withheld for tax obligations upon restricted stock unit vesting.

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, reported a disposition of 613 common shares for tax withholding purposes related to restricted stock unit vesting.

Acrivon Therapeutics' CEO and EVP reported shares withheld for tax obligations upon restricted stock unit vesting.

Acrivon Therapeutics' CFO, Adam D. Levy, reported the withholding of 1,164 common shares for tax obligations related to restricted stock unit vesting.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported the withholding of 558 shares of common stock to satisfy tax obligations upon the vesting of restricted stock units, effective July 17, 2025.

RA Capital Management, L.P., a significant shareholder and director of Acrivon Therapeutics, Inc., reported the acquisition of 20,275 stock options through an affiliated director's grant.

Acrivon Therapeutics, Inc. Director Derek DiRocco was granted 20,275 stock options with an exercise price of $1.2, though he disclaims beneficial ownership as the options are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II.

Acrivon Therapeutics, Inc. director Michael Tomsicek was granted 20,275 stock options with an exercise price of $1.20, vesting prior to the next annual stockholders' meeting.